Literature DB >> 25169483

Systemic analysis on risk factors for breast cancer related lymphedema.

Ya-Qun Zhu1, Yu-Huan Xie, Feng-Huan Liu, Qi Guo, Pei-Pei Shen, Ye Tian.   

Abstract

BACKGROUND: To evaluate risk factors for upper extremity lymphedema due to breast cancer surgery.
MATERIALS AND METHODS: Clinical studies published on PubMed, Ovid, EMbase, and Cochrane Library from January 1996 to December 2012 were selected.
RESULTS: Twenty-five studies were identified, including 12,104 patients. Six risk factors related to the incidence of lymphedema after breast cancer treatment were detected: axillary lymph node dissection (OR=3.73, 95%CI 1.16 to 11.96), postoperative complications (OR=2.64, 95%CI 1.10 to 6.30), hypertension (OR=1.83, 95%CI 1.38 to 2.42), high body mass index (OR=1.80, 95%CI 1.30 to 2.49), chemotherapy (OR=1.38, 95%CI 1.07 to 1.79) and radiotherapy (OR=1.35, 95%CI 1.10 to 1.66). We found significant protective factors for lymphedema: pathologic T classification (OR=0.57, 95%CI 0.36 to 0.91) and stage (OR=0.60, 95%CI 0.39 to 0.93), while some factors, like age, number of positive lymph nodes, number of lymph node dissection, demonstrated no obvious correlation.
CONCLUSIONS: Axillary lymph node dissection, postoperative complications, hypertension, body mass index, chemotherapy, radiotherapy are risk factors for lymphedema after breast cancer treatment. Attention should be paid to patients with risk factors to prevent the occurrence of lymphedema.

Entities:  

Mesh:

Year:  2014        PMID: 25169483     DOI: 10.7314/apjcp.2014.15.16.6535

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

1.  Risk Factors for Lymphedema in Breast Cancer Survivors Following Axillary Lymph Node Dissection.

Authors:  Yoshiteru Akezaki; Ritsuko Tominaga; Masato Kikuuchi; Hideaki Kurokawa; Makiko Hamada; Kenjiro Aogi; Shozo Ohsumi; Tetsuya Tsuji; Susumu Kawamura; Shinsuke Sugihara
Journal:  Prog Rehabil Med       Date:  2019-11-23

2.  A model to assess the risk of peripherally inserted central venous catheter-related thrombosis in patients with breast cancer: a retrospective cohort study.

Authors:  Si-Yi Peng; Tao Wei; Xu-Ying Li; Zhong Yuan; Qin Lin
Journal:  Support Care Cancer       Date:  2021-08-25       Impact factor: 3.603

3.  Obese patients have higher risk of breast cancer-related lymphedema than overweight patients after breast cancer: a meta-analysis.

Authors:  Ruxing Wu; Xiaoyuan Huang; Xiyuan Dong; Hanwang Zhang; Liang Zhuang
Journal:  Ann Transl Med       Date:  2019-04

4.  Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.

Authors:  Meyha N Swaroop; Chantal M Ferguson; Nora K Horick; Melissa N Skolny; Cynthia L Miller; Lauren S Jammallo; Cheryl L Brunelle; Jean A O'Toole; Steven J Isakoff; Michelle C Specht; Alphonse G Taghian
Journal:  Breast Cancer Res Treat       Date:  2015-05-05       Impact factor: 4.872

5.  Current Treatments for Breast Cancer-Related Lymphoedema: A Systematic Review

Authors:  Lun Li; Liqin Yuan; Xianyu Chen; Quan Wang; Jinhui Tian; Kehu Yang; Enxiang Zhou
Journal:  Asian Pac J Cancer Prev       Date:  2016-11-01

6.  Discussion of relationships among changes of pathological indicators, postoperative lymphedema of the upper limb, and prognosis of patients with breast cancer.

Authors:  Xiping Zhang; Binbin Tang; Dehong Zou; Hongjian Yang; Enqi Qiao; Xiangming He; Feijiang Yu
Journal:  Biosci Rep       Date:  2019-04-16       Impact factor: 3.840

7.  Late radiation sequelae as a consequence of breast-conserving therapy with cobalt irradiation aggravated by various risk factors.

Authors:  R M Hermann; B Clausing; J Mayer; U M Carl; M Nitsche
Journal:  BJR Case Rep       Date:  2015-05-25

8.  Development and Validation of a Risk Model for Breast Cancer-Related Lymphedema.

Authors:  Jennifer Yin Yee Kwan; Petra Famiyeh; Jie Su; Wei Xu; Benjamin Yin Ming Kwan; Jennifer M Jones; Eugene Chang; Kenneth W Yip; Fei-Fei Liu
Journal:  JAMA Netw Open       Date:  2020-11-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.